Skip to content
Peptigraph home

5-Amino-1MQ vs SLU-PP-332: What the Research Shows

5-Amino-1MQ and SLU-PP-332 side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
NNMT inhibitor (not a peptide)Not FDA approved · research chemical5-Amino-1MQNNMT inhibitor (not a peptide) with no human studies; in diet-induced obese mice, 5-amino-1MQ plus a low-fat diet promoted whole-body adiposity and weight loss.[2]GLP-1 & metabolicERR agonist (not a peptide)Not FDA approved · research chemicalSLU-PP-332Experimental ERR agonist (not a peptide) with no human studies; in mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise.[6]GLP-1 & metabolic
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider 5-Amino-1MQ if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

Consider SLU-PP-332 if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

What they have in common

  • Only animal or lab studies of 5-amino-1MQ were found (e.g. obese mice): combined with a low-fat diet it promoted marked loss of adiposity and weight[2]
  • Only animal or lab studies of SLU-PP-332 were found (e.g. mouse): In mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise effects on whole-body metabolism.[6]
Neither is FDA approved for any use in people. Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 5 of 11 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026, WADA, Half-life, Evidence strength are the same or both unknown.

Field5-Amino-1MQSLU-PP-332
ClassNNMT inhibitor (not a peptide)ERR agonist (not a peptide)
Also called5-amino, 1MQslupp, SLU-PP
Human studies we summarised0 human (0 randomized or controlled) of 4 summarised0 human (0 randomized or controlled) of 7 summarised
Typical study dosesNot reported in study abstractsPubMed search, 11 Oct 2026
Vial sizes sold5 mg, 10 mg5 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

5-Amino-1MQ and SLU-PP-332 together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Open the stack page

Two non-peptide small molecules aimed at different targets

SLU-PP-332 is described as a synthetic agonist of the ERR family of nuclear receptors. 5-amino-1MQ is an NNMT enzyme inhibitor, so the two act on different targets.[12]

In mice, SLU-PP-332 raised energy expenditure and fatty acid oxidation and mimicked exercise effects on whole-body metabolism.[6]

In mouse models of metabolic syndrome, the ERR agonist also reduced obesity and improved insulin sensitivity.[6]

SLU-PP-332 beyond body weight, in mice and cells

In a mouse model of pressure-overload heart failure, SLU-PP-332 and a related compound, SLU-PP-915, improved ejection fraction and survival.[13]

In aging mice, 8 weeks of a pan-ERR agonist reversed age-related albuminuria and podocyte loss in the kidney.[14]

The only human-derived work cited used myoblasts cultured from muscle biopsies of inactive women, treated with SLU-PP-332 in the dish. It is cell data, not a result in people.[15]

A recent review of the pan-ERR agonists says clinical trials are needed to confirm efficacy and safety in humans.[16]

Anti-doping note

A paper on SLU-PP-332 metabolites states that WADA prohibits the use of exercise mimetics and metabolic modulators in sports.[17]

Common questions

Is SLU-PP-332 stronger than 5-amino-1MQ?

There is no basis to rank them. Both have animal or cell data only, and the endpoints differ: exercise-like metabolism and heart function for SLU-PP-332, adiposity alongside a diet change for 5-amino-1MQ.[6]

Are SLU-PP-332 and 5-amino-1MQ peptides?

Neither is described as a peptide in the cited abstracts. The 5MQ cell work calls it a small molecule inhibitor of NNMT, and SLU-PP-332 is described as a synthetic ERR agonist.[3]

Has SLU-PP-332 been tested in humans?

Not in the abstracts reviewed. The only human-derived material was cultured muscle cells, and a recent review says clinical trials are still needed.[16]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
  3. 3Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021PMID 33645410Accessed 2 Oct 2026
  4. 4PubMed search: "5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab] (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: nicotinamide N-methyltransferase[tiab] AND (quinolinium[tiab] OR 5-amino-1MQ[tiab] OR "5-amino-1-methylquinolinium"[tiab] OR 5MQ[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
  7. 7PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (0 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  11. 11PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  12. 12Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
  13. 13Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.Circulation · 2024PMID 37961903Accessed 2 Oct 2026
  14. 14Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.The American journal of pathology · 2023PMID 37717940Accessed 2 Oct 2026
  15. 15Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025PMID 40692696Accessed 2 Oct 2026
  16. 16[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026
  17. 17Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026

Found an error? Report a correction.